Josh Silverman PhD

Josh Silverman, Ph.D. is the Chief Technology Officer and Founder of Calysta. He was appointed CTO in 2014, and previously served as the company’s Chief Scientific Officer. Dr. Silverman is an experienced biotechnology entrepreneur with a history of successful development of novel technology platforms. Prior to founding Calysta, Dr. Silverman held positions at two public biotechnology companies, Maxygen, Inc. and Amgen, Inc. as well as serving as VP of Product development for Amunix, Inc. He has been involved in the founding and financing of five startup biotechnology companies (Avidia, Versartis, Diartis, Siluria, and Calysta). His efforts contributed to raising over $110 million in equity financing across these companies, as well as the sale of Avidia for $290M three years after founding the company and an IPO by Versartis in 2014 which raised 126 million.

Dr. Silverman is generally interested in tools and applications of biological engineering as a robust and predictable engineering discipline. He serves as an advisor for a number of biotechnology companies and is a frequent speaker at scientific meetings. He has been directly involved in successfully bringing three novel biopharmaceuticals from early phase research into clinical trials, with experience in both regulatory filings and drug manufacturing. He is an author on more than 10 scientific publications as well as over 30 patents and pending patent applications. He received his B.Sc. in Molecular Biology from UC San Diego and Ph.D. in Biochemistry from Stanford University.